Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011 by Cardiff and Vale University Health Board.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Cardiff University
Information provided by (Responsible Party):
Matt P Wise, Cardiff and Vale University Health Board
ClinicalTrials.gov Identifier:
NCT01482988
First received: November 29, 2011
Last updated: November 30, 2011
Last verified: November 2011
  Purpose

The principal aim of this study is to establish if a polymorphism in a gene important for innate immunity to fungi represents a significant risk factor for the development of Candida colonisation and subsequent invasive candidosis in critically ill patients. Incorporation of a screening programme onto a risk-based algorithm for critical care patients would allow more effective targeting of molecular diagnostic tests, anti-fungal prophylaxis and targeted treatment. Sequential critical care patients will be screened for gene polymorphisms and undergo regular screening for Candida colonization.


Condition
Critically Ill

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients

Resource links provided by NLM:


Further study details as provided by Cardiff and Vale University Health Board:

Estimated Enrollment: 600
Study Start Date: December 2011
Groups/Cohorts
Critical care patients antipated to stay more than 72 hours

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Critical care patients predicted to stay more than 72 hours

Criteria

Inclusion Criteria:

  • Patients aged > 18 years
  • Patients with anticipated or actual critical care unit stay > 72 hours
  • Consent or assent (if patient lacks capacity) obtained

Exclusion Criteria:

  • Age < 18 years
  • Length of predicted stay on critical care < 72 hours consent or assent not obtained
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01482988

Contacts
Contact: Matt P Wise +44 2920 747747 ext 3608 mattwise@doctors.org.uk
Contact: Nicki Haskins +44 2920 747747 ext 3608 nicki.haskins@wales.nhs.uk

Locations
United Kingdom
Critical Care Unit Not yet recruiting
University Hospital of Wales, Cardiff, United Kingdom, CF14 4XW
Contact: Matt P Wise    +44 2920 747747 ext 3608    mattwise@doctors.org.uk   
Sub-Investigator: Matt P Wise         
Sponsors and Collaborators
Cardiff and Vale University Health Board
Cardiff University
Investigators
Principal Investigator: Rosemary Barnes Cardiff University
Principal Investigator: Matt P Wise Cardiff and Vale Local Health Board
  More Information

No publications provided

Responsible Party: Matt P Wise, Critical Care Consultant, Cardiff and Vale University Health Board
ClinicalTrials.gov Identifier: NCT01482988     History of Changes
Other Study ID Numbers: 11/WA/0340
Study First Received: November 29, 2011
Last Updated: November 30, 2011
Health Authority: Wales:Cardiff University
Wales:Cardiff and Vale University Health Board

Keywords provided by Cardiff and Vale University Health Board:
prevalence of the Dectin-1 polymorphism (Tyr238X)

Additional relevant MeSH terms:
Critical Illness
Disease Attributes
Pathologic Processes

ClinicalTrials.gov processed this record on September 18, 2014